Auxilius Pharma is dedicated to enhancing patient care through the development of innovative pharmaceutical treatments, particularly focusing on extended-release formulations. Their lead asset, AUX-001, is a promising new medication for chronic stable angina, which has undergone a Phase 1a study to assess its safety, tolerability, and pharmacokinetics. The company employs a strategic approach to drug development by utilizing the 505(b)(2) regulatory pathway in the United States. This pathway allows them to leverage existing safety and efficacy data, significantly reducing the clinical work required to bring their products to market, thereby shortening development cycles and minimizing costs and risks.

The company emphasizes the creation of value-added medications (VAMs), which are established drugs that have been reformulated to enhance their therapeutic benefits for patients, healthcare providers, and payers. Auxilius Pharma's pipeline includes a range of projects that address high unmet clinical needs, with a focus on building a strong intellectual property position. Their development strategy not only aims to improve patient outcomes but also seeks to streamline the regulatory process, allowing for accelerated market entry and exclusivity, which is crucial for maintaining a competitive edge in the pharmaceutical industry.

United States

Auxilius Pharma is an emerging specialized pharmaceutical company with a focus on further developing and optimizing medications well established in some markets but not in the others, for the benefit of patients and to address major unmet needs in an increasingly cost conscious health care market environment. We are a versatile team with multifunctional healthcare experience in both the US and EU. We feature diverse backgrounds and strong core competencies in pharmaceutical marketing, drug development, pharmacology, health care management, corporate finance, and asset management.

Auxilius Pharma

Company Details